Companies › Cybin IRL
1 active drug program in 3 registered trials: 2 Phase 3, 1 Phase 2; Psychiatry; next expected readout Jun 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| CYB003 Deuterated psilocin analog | HTR2A | Phase 3 | Major Depressive Disorder; Major Depressive Disorder (MDD); Depression | Jun 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06564818 | CYB003 | Phase 3 | Major Depressive Disorder | Psychiatry | Sep 2026 |
| NCT06793397 | CYB003 | Phase 3 | Major Depressive Disorder (MDD) | Psychiatry | Jun 2027 |
| NCT06820723 | CYB003 | Phase 2 | Depression | Psychiatry | Nov 2028 |
NeuroRx Intra-Cellular Therapies COMPASS Pathways Gedeon Richter Beijing Union Pharmaceutical Factory
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.